PT  - JOURNAL ARTICLE
AU  - Ernesto Rossi
AU  - Giovanni Schinzari
AU  - Giampaolo Tortora
TI  - Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
AID  - 10.1136/jitc-2020-000952
DP  - 2020 Jul 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e000952
VI  - 8
IP  - 2
4099  - http://jitc.bmj.com/content/8/2/e000952.short
4100  - http://jitc.bmj.com/content/8/2/e000952.full
SO  - J Immunother Cancer2020 Jul 01; 8
AB  - Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed to the coronavirus infection as well as to an immune-related adverse event. Identifying the exact cause of a pneumonitis in patients on treatment with immunotherapy is crucial to promptly start the most appropriate treatment. The proper management of immune checkpoint inhibitors for the risk of pneumonia must take into account a series of parameters. Accurate attention should be payed to symptoms like cough, fever and dyspnea during immunotherapy.